Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Current Liabilities
All obligations due within one year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 24.5% from a year ago
Total current liabilities stood at $61.16M at the end of Q1 FY2026, up 24.5% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +34.1% a year.
Context
- Total current liabilities amounted to 8.2% of total assets at the end of Q1 FY2026, down 6.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +24.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 62.65M USD
- Year-over-year change
- +9.4%
- 3-year CAGR
- +34.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.65M | +9.4% |
| FY2024 | 2024-12-31 | 57.29M | +146.3% |
| FY2023 | 2023-12-31 | 23.26M | -10.4% |
| FY2022 | 2022-12-31 | 25.97M | — |
Total Current Liabilities vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total current liabilities of $61.16M is the 2nd highest of the 8 companies compared; the peer median is $27.37M.
- Its year-over-year change of +24.5% is the 5th highest of 7, against a peer median of +35.0%.
- Total current liabilities amounts to 8.2% of total assets for ZBIO, versus a peer median of 13.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $104.02M | +64.5% | +34.1% | 13.7% | |
| Mar 2026 | $61.16M | +24.5% | +34.1% | 8.2% | |
| Mar 2026 | $35.94M | +7.1% | +24.0% | 13.7% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M | — | — | 11.4% |
| Mar 2026 | $27.37M | +27.2% | +9.3% | 13.8% | |
UPBUpstream Bio, Inc. | Mar 2026 | $13.67M | +42.9% | +40.4% | 4.3% |
| Dec 2025 | $11.21M | +52.5% | +18.9% | 97.5% | |
| Mar 2026 | $10.67M | -26.8% | -41.9% | 16.8% | |
| Peer median (excluding ZBIO) | $27.37M | +35.0% | +21.5% | 13.7% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.